GGrantIndex
← Leaderboards

David Ian Quinn

University Of Southern California

$4,779,068
Attributed
$7,690,320
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $949K · FY200521
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$7,690,320 · 9

By mechanism

P30$3,025,178 · 1
U10$3,023,086 · 1
UG1$1,343,792 · 1
M01$298,264 · 6

Top collaborators

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Research Personnel

Research focus

Research PersonnelResourcesFundingClinical ResearchResearch ActivityClinical TrialsGrantAreaMalignant NeoplasmsResponseToxic EffectSafetyUsc/Norris Comprehensive Cancer Center And HospitalCancer CenterMedical CenterCountyLos AngelesDesignCholangiocarcinomaDrug DevelopmentData AcquisitionCancer TherapyBaseDedications

Grant awards (19)

NCTN - Network Lead Academic Participating Site: USC$409,376
UG1 · FY2021 · CA
NCTN - Network Lead Academic Participating Site: USC$464,856
UG1 · FY2020 · CA
NCTN - Network Lead Academic Participating Site: USC$469,560
UG1 · FY2019 · CA
NCI NCTN- Network Lead Academic Participating Site: USC$523,827
U10 · FY2018 · CA
NCI NCTN- Network Lead Academic Participating Site: USC$596,003
U10 · FY2017 · CA
NCI NCTN- Network Lead Academic Participating Site: USC$627,370
U10 · FY2016 · CA
NCI NCTN- Network Lead Academic Participating Site: USC$646,885
U10 · FY2015 · CA
NCI NCTN- Network Lead Academic Participating Site: USC$629,001
U10 · FY2014 · CA
Clinical Investigations Support Office$703,609
P30 · FY2010 · CA · contact PI
Clinical Investigations Support Office$713,631
P30 · FY2009 · CA · contact PI
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR$194,793
M01 · FY2009 · RR · contact PI
A PHASE I STUDY OF VEGF- ANTISENSE OLIGONUCLEOTIDE (VEGF-AS) GIVEN AS A DAILY$40,583
M01 · FY2009 · RR · contact PI
Clinical Investigations Support Office$610,976
P30 · FY2008 · CA · contact PI
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR$26,437
M01 · FY2008 · RR · contact PI
Clinical Investigations Support Office$687,042
P30 · FY2007 · CA · contact PI
A PHASE I/II STUDY OF E7389 HALICHONDRIN B ANALOG IN METASTATIC UROTHELIAL TR$21,320
M01 · FY2007 · RR · contact PI
Clinical Investigations Support Office$309,920
P30 · FY2006 · CA · contact PI
PROTOCOL FOR ASSESSMENT OF GEMCITABINE AND PACLITAXEL FOR METASTIC UROTHELIAL$13,064
M01 · FY2006 · RR · contact PI
PHASE II MULTI-CENTER TRIAL OF BAY 56-3722 (BAY 38-3441) IN PATIENTS WITH$2,067
M01 · FY2005 · RR